相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome
Walter Ageno et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia A Systematic Review
Derek K. Chu et al.
ANNALS OF INTERNAL MEDICINE (2017)
Management of venous thromboembolism in myeloproliferative neoplasms
Tiziano Barbui et al.
CURRENT OPINION IN HEMATOLOGY (2017)
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)
Iris Appelmann et al.
ANNALS OF HEMATOLOGY (2016)
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis
Bethany T. Samuelson et al.
BLOOD COAGULATION & FIBRINOLYSIS (2016)
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
V. De Stefano et al.
LEUKEMIA (2016)
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Juan-Carlos Hernandez-Boluda et al.
ANNALS OF HEMATOLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
Gilles Bonicelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Splanchnic vein thrombosis in myeloproliferative neoplasms
Mallika Sekhar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice
A. Tefferi et al.
LEUKEMIA (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
Veronika Buxhofer-Ausch et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
Peter J. Campbell et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
G. Finazzi et al.
LEUKEMIA (2012)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
Alessandro M. Vannucchi et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2011)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Thrombohemorrhagic complications of myeloproliferative disorders
Emmanouil Papadakis et al.
BLOOD REVIEWS (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
Alessandra Carobbio et al.
EXPERIMENTAL HEMATOLOGY (2009)
Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia
Valerio De Stefano et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia
Issa J. Dahabreh et al.
LEUKEMIA RESEARCH (2009)
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
Federico Lussana et al.
THROMBOSIS RESEARCH (2009)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia:: a retrospective survey
Marco Ruggeri et al.
BLOOD (2008)
Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain
Panayiotis D. Ziakas
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Leukocytosis and risk stratification assessment in essential thrombocythemia
Alessandra Carobbio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia
Naseema Gangat et al.
CANCER (2006)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Factor V Leiden mutation carriership and venous thromboembolism in Polycythemia Vera and Essential Thrombocythemia
M Ruggeri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
分享论文
